Very-high-risk localized prostate cancer: Definition and outcomes

D. Sundi, V. M. Wang, Phillip Martin Pierorazio, Misop Han, Trinity Bivalacqua, M. W. Ball, Emmanuel Antonarakis, Alan Wayne Partin, E. M. Schaeffer, A. E. Ross

Research output: Contribution to journalArticle

Abstract

Background:Outcomes in men with National Comprehensive Cancer Network (NCCN) high-risk prostate cancer (PCa) can vary substantially - some will have excellent cancer-specific survival, whereas others will experience early metastasis even after aggressive local treatments. Current nomograms, which yield continuous risk probabilities, do not separate high-risk PCa into distinct sub-strata. Here, we derive a binary definition of very-high-risk (VHR) localized PCa to aid in risk stratification at diagnosis and selection of therapy.Methods:We queried the Johns Hopkins radical prostatectomy database to identify 753 men with NCCN high-risk localized PCa (Gleason sum 8-10, PSA >20 ng ml -1, or clinical stage ≥T3). Twenty-eight alternate permutations of adverse grade, stage and cancer volume were compared by their hazard ratios for metastasis and cancer-specific mortality. VHR criteria with top-ranking hazard ratios were further evaluated by multivariable analyses and inclusion of a clinically meaningful proportion of the high-risk cohort.Results:The VHR cohort was best defined by primary pattern 5 present on biopsy, or ≥5 cores with Gleason sum 8-10, or multiple NCCN high-risk features. These criteria encompassed 15.1% of the NCCN high-risk cohort. Compared with other high-risk men, VHR men were at significantly higher risk for metastasis (hazard ratio 2.75) and cancer-specific mortality (hazard ratio 3.44) (P

Original languageEnglish (US)
Pages (from-to)57-63
Number of pages7
JournalProstate Cancer and Prostatic Diseases
Volume17
Issue number1
DOIs
StatePublished - Mar 2014

Fingerprint

Prostatic Neoplasms
Neoplasms
Neoplasm Metastasis
Nomograms
Mortality
Prostatectomy
Databases
Biopsy
Survival

Keywords

  • high-risk prostate cancer
  • metastasis
  • survival

ASJC Scopus subject areas

  • Oncology
  • Urology
  • Cancer Research
  • Medicine(all)

Cite this

Very-high-risk localized prostate cancer : Definition and outcomes. / Sundi, D.; Wang, V. M.; Pierorazio, Phillip Martin; Han, Misop; Bivalacqua, Trinity; Ball, M. W.; Antonarakis, Emmanuel; Partin, Alan Wayne; Schaeffer, E. M.; Ross, A. E.

In: Prostate Cancer and Prostatic Diseases, Vol. 17, No. 1, 03.2014, p. 57-63.

Research output: Contribution to journalArticle

@article{cf2f837661ab452a9f25ec05051d2d0c,
title = "Very-high-risk localized prostate cancer: Definition and outcomes",
abstract = "Background:Outcomes in men with National Comprehensive Cancer Network (NCCN) high-risk prostate cancer (PCa) can vary substantially - some will have excellent cancer-specific survival, whereas others will experience early metastasis even after aggressive local treatments. Current nomograms, which yield continuous risk probabilities, do not separate high-risk PCa into distinct sub-strata. Here, we derive a binary definition of very-high-risk (VHR) localized PCa to aid in risk stratification at diagnosis and selection of therapy.Methods:We queried the Johns Hopkins radical prostatectomy database to identify 753 men with NCCN high-risk localized PCa (Gleason sum 8-10, PSA >20 ng ml -1, or clinical stage ≥T3). Twenty-eight alternate permutations of adverse grade, stage and cancer volume were compared by their hazard ratios for metastasis and cancer-specific mortality. VHR criteria with top-ranking hazard ratios were further evaluated by multivariable analyses and inclusion of a clinically meaningful proportion of the high-risk cohort.Results:The VHR cohort was best defined by primary pattern 5 present on biopsy, or ≥5 cores with Gleason sum 8-10, or multiple NCCN high-risk features. These criteria encompassed 15.1{\%} of the NCCN high-risk cohort. Compared with other high-risk men, VHR men were at significantly higher risk for metastasis (hazard ratio 2.75) and cancer-specific mortality (hazard ratio 3.44) (P",
keywords = "high-risk prostate cancer, metastasis, survival",
author = "D. Sundi and Wang, {V. M.} and Pierorazio, {Phillip Martin} and Misop Han and Trinity Bivalacqua and Ball, {M. W.} and Emmanuel Antonarakis and Partin, {Alan Wayne} and Schaeffer, {E. M.} and Ross, {A. E.}",
year = "2014",
month = "3",
doi = "10.1038/pcan.2013.46",
language = "English (US)",
volume = "17",
pages = "57--63",
journal = "Prostate Cancer and Prostatic Diseases",
issn = "1365-7852",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Very-high-risk localized prostate cancer

T2 - Definition and outcomes

AU - Sundi, D.

AU - Wang, V. M.

AU - Pierorazio, Phillip Martin

AU - Han, Misop

AU - Bivalacqua, Trinity

AU - Ball, M. W.

AU - Antonarakis, Emmanuel

AU - Partin, Alan Wayne

AU - Schaeffer, E. M.

AU - Ross, A. E.

PY - 2014/3

Y1 - 2014/3

N2 - Background:Outcomes in men with National Comprehensive Cancer Network (NCCN) high-risk prostate cancer (PCa) can vary substantially - some will have excellent cancer-specific survival, whereas others will experience early metastasis even after aggressive local treatments. Current nomograms, which yield continuous risk probabilities, do not separate high-risk PCa into distinct sub-strata. Here, we derive a binary definition of very-high-risk (VHR) localized PCa to aid in risk stratification at diagnosis and selection of therapy.Methods:We queried the Johns Hopkins radical prostatectomy database to identify 753 men with NCCN high-risk localized PCa (Gleason sum 8-10, PSA >20 ng ml -1, or clinical stage ≥T3). Twenty-eight alternate permutations of adverse grade, stage and cancer volume were compared by their hazard ratios for metastasis and cancer-specific mortality. VHR criteria with top-ranking hazard ratios were further evaluated by multivariable analyses and inclusion of a clinically meaningful proportion of the high-risk cohort.Results:The VHR cohort was best defined by primary pattern 5 present on biopsy, or ≥5 cores with Gleason sum 8-10, or multiple NCCN high-risk features. These criteria encompassed 15.1% of the NCCN high-risk cohort. Compared with other high-risk men, VHR men were at significantly higher risk for metastasis (hazard ratio 2.75) and cancer-specific mortality (hazard ratio 3.44) (P

AB - Background:Outcomes in men with National Comprehensive Cancer Network (NCCN) high-risk prostate cancer (PCa) can vary substantially - some will have excellent cancer-specific survival, whereas others will experience early metastasis even after aggressive local treatments. Current nomograms, which yield continuous risk probabilities, do not separate high-risk PCa into distinct sub-strata. Here, we derive a binary definition of very-high-risk (VHR) localized PCa to aid in risk stratification at diagnosis and selection of therapy.Methods:We queried the Johns Hopkins radical prostatectomy database to identify 753 men with NCCN high-risk localized PCa (Gleason sum 8-10, PSA >20 ng ml -1, or clinical stage ≥T3). Twenty-eight alternate permutations of adverse grade, stage and cancer volume were compared by their hazard ratios for metastasis and cancer-specific mortality. VHR criteria with top-ranking hazard ratios were further evaluated by multivariable analyses and inclusion of a clinically meaningful proportion of the high-risk cohort.Results:The VHR cohort was best defined by primary pattern 5 present on biopsy, or ≥5 cores with Gleason sum 8-10, or multiple NCCN high-risk features. These criteria encompassed 15.1% of the NCCN high-risk cohort. Compared with other high-risk men, VHR men were at significantly higher risk for metastasis (hazard ratio 2.75) and cancer-specific mortality (hazard ratio 3.44) (P

KW - high-risk prostate cancer

KW - metastasis

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=84894079536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894079536&partnerID=8YFLogxK

U2 - 10.1038/pcan.2013.46

DO - 10.1038/pcan.2013.46

M3 - Article

C2 - 24189998

AN - SCOPUS:84894079536

VL - 17

SP - 57

EP - 63

JO - Prostate Cancer and Prostatic Diseases

JF - Prostate Cancer and Prostatic Diseases

SN - 1365-7852

IS - 1

ER -